Skip to Main Content

Paper Details

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Cancer Discov
623
2015
CDKN2A, CDKN2A/B, HSP90, KC, KC tumors, KEAP1, KL, KL cells, KL tumors, KP tumors, KRAS, KRAS-mutant, KRAS-mutant lung, KRAS-mutant lung adenocarcinoma, LKB1, NKX2-1, PD-L1, STK11, TP53, TTF1, lung adenocarcinoma, mTORC1
Author NameAffiliation
Lixia DiaoThe University of Texas MD Anderson Cancer Center
Jianjun ZhangThe University of Texas MD Anderson Cancer Center
Michael PeytonHamon Center for Therapeutic Oncology Research and Simmons Cancer Center, The University of Texas Southwestern Medical Center
Kevin R CoombesWexner Medical Center, The Ohio State University
Timothy P HeffernanInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center
Vincent A MillerFoundation Medicine
John N WeinsteinThe University of Texas MD Anderson Cancer Center
John N WeinsteinThe University of Texas MD Anderson Cancer Center
Roy S HerbstYale Cancer Center and Smilow Cancer Hospital at Yale-New Haven
Jianhua ZhangInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center
Jianhua ZhangInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center
Gordon B MillsThe University of Texas MD Anderson Cancer Center
Gordon B MillsThe University of Texas MD Anderson Cancer Center
John D MinnaHamon Center for Therapeutic Oncology Research and Simmons Cancer Center, The University of Texas Southwestern Medical Center
Phillip A FutrealThe University of Texas MD Anderson Cancer Center
  • 1 - 15

Datasets

Release 1.2